Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma

Lu, Ye; Liu, Jie; Lin, Chengzhao; Wang, Haijian; Jiang, Ying; Wang, Jiyao; Yang, Pengyuan; He, Fuchu

doi:10.1186/1471-230X-10-115

Table 3 List of identified proteins ^a

From: Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma

Spot No.^b)	Protein ID^c)	Procession No.^d)	Protein Score^e)	C.I.%^f)	Ion Score^e)	C.I.%^f)	Peptide	MW(kDa)^g) theoretical/observed	pI^g) theoretical/observed	Appearance^h)	Pvalue^I)
1	α-2 macroglobulin	P01023	341	100	185	100	34	163/90	6/5.6	12(18)	0.03
2	α-2 macroglobulin	P01023	341	100	185	100	34	163/90	6/5.7	12(18)	0.03
3	α-2 macroglobulin	P01023	341	100	185	100	34	163/90	6/5.8	12(18)	0.03
4	α-2 macroglobulin	P01023	341	100	185	100	34	163/90	6/5.9	12(18)	0.03
5	Serotransferrin	P02787	297	100	119	100	33	77/80	6.81/6.5	15(18)	0.012
6	Serotransferrin	P02787	78	99.992	37	99.6	13	77/80	6.81/6.5	12(18)	0.015
7	Hemopexin	P02790	120	100	44	99.996	19	52/60	6.55/4.5	15(18)	0.021
8	Hemopexin	P02790	178	100	80	100	19	52/60	6.55/4.5	15(18)	0.025
9	LRG	P02750	108	100	55	100	15	34/34	5.66/5.4	18(18)	0.029
10	LRG	P02750	199	100	134	100	18	34/34	5.66/5.4	18(18)	0.041
11	Fibrogen γ chain	P02679	146	100	40	99.987	18	50/50	5.61/5.9	15(18)	0.03
12	α-1 antitrypsin	P01009	76	99.986	33	99.942	11	47/56	5.37/5.2	12(18)	0.011
13	APO-AIV	P06727	143	100	41	99.991	15	45/45	5.28/5.2	18(18)	0.021
14	APO-AIV	P06727	143	100	41	99.991	15	45/45	5.28/5.2	18(18)	0.021
15	Fibrogen β chain	P02675	341	100	150	100	36	56/46	8.54/5.5	15(18)	0.021
16	Clusterin	P10909	144	100	86	100	17	52/40	5.89/5.0	18(18)	0.013
17	Clusterin	P10909	130	100	71	100	17	52/39	5.89/5.2	18(18)	0.013
18	Clusterin	P10909	74	99.98	59	100	12	52/35	5.89/5.3	18(18)	0.013
19	Clusterin	P10909	127	100	74	100	17	52/34	5.89/5.4	18(18)	0.016
20	APO-A1	P02647	255	100	87	100	28	31/28	5.56/5.2	18(18)	0.013
21	APO-A1	P02647	364	100	107	100	33	31/28	5.56/5.3	18(18)	0.013
22	APO-A1	P02647	214	100	21	99.305	25	31/28	5.56/5.3	18(18)	0.021
23	APO-A1	P02647	404	100	113	100	39	31/28	5.56/5.4	18(18)	0.021
24	Thioredoxin peroxidase 1	P32119	263	100	143	100	16	22/21	5.66/5.4	15(18)	0.021
25	HP-2	P00738	71	99.961	19	99.13	10	45/20	6.13/5.4	18(18)	0.0031
26	HP-2	P00737	91	100	58	100	12	38/20	6.13/5.6	18(18)	0.0051
27	HP-2	P00738	88	100	58	100	11	45/20	6.13/6.3	18(18)	0.0051
28	Prealbulmn	P02766	53	97.616	25	99.732	7	16/16	5.52/5.2	18(18)	0.0067
29	Prealbulmn	P02766	56	98.66	54	99.944	7	16/16	5.52/5.3	15(18)	0.0067
30	Prealbulmn	P02766	127	100	64	100	10	16/16	5.52/5.6	12(18)	0.013

a) Spots for which the volume |ratio| ≥ 1.5 (t test) and P ≤ 0.05 (one-way ANOVA) based on DeCyder software analysis were identified by MALDI-TOF/TOF MS.
b) Spots referring to Figure 2.
c) Spots in the same line were identified as same protein.
d) Protein ID accessed from Swiss-Prot database by data searching.
e) Total protein score analyzed by MS and total ion score of the peptide analyzed by MS/MS.
f) Confidence of protein score and ion score.
g) Theoretical MW and pI accessed from UniProt database.
h) Number of the gels containing the protein spot.
i) P value calculated by one-way ANOVA analysis.

Back to article page

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Gastroenterology

Contact us